DigestRedComo funciona
Red
/
Empresas
AC
No verificado

AC Immune SA

Sobre qué escribimos

Anuncios brevesBiotecnologíaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

33 Comunicados de prensa

Ver todos los comunicados de prensa
23/09/2026
Biotecnología
Anuncios breves
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
20/08/2026
Biotecnología
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
11/08/2026
Biotecnología
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
05/08/2026
Biotecnología
Gestión empresarial/Administración de Empresas
AC Immune First Half 2026 Financial and Corporate Update
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
07/07/2026
Biotecnología
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
30/06/2026
Biotecnología
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
11/06/2026
Biotecnología
Finanzas
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
Press Release cover image
22/05/2026
Biotecnología
Medicina Salud Bienestar
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
12/05/2026
Biotecnología
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0
30/04/2026
Biotecnología
Gestión empresarial/Administración de Empresas
AC Immune First Quarter 2026 Financial and Corporate Updates
Fuente
AC Immune SA
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0